2. Academic Validation
  3. Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies

Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies

  • J Med Chem. 2023 Mar 23;66(6):4179-4196. doi: 10.1021/acs.jmedchem.3c00074.
Emmanuel A Meyer 1,  Päivi Äänismaa 2,  Eric A Ertel 3,  Eva Hühn 2,  Daniel S Strasser 4,  Markus Rey 5,  Mark J Murphy 6,  Marianne M Martinic 7,  Laetitia Pouzol 7,  Sylvie Froidevaux 8,  Marcel P Keller 6,  Eva Caroff 1
Affiliations

Affiliations

  • 1 Chemistry Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
  • 2 DMPK, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
  • 3 Electrophysiology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
  • 4 Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
  • 5 Cardiovascular Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
  • 6 Biology Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
  • 7 Pharmacology Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
  • 8 Idorsia Pharmaceuticals Ltd, Bendorf 68480, France.
PMID: 36883854 DOI: 10.1021/acs.jmedchem.3c00074
Abstract

The CXCR3 Chemokine Receptor is a G protein-coupled receptor mainly expressed on immune cells from the lymphoid lineage, including activated T cells. Binding of its inducible chemokine ligands CXCL9, CXCL10, and CXCL11 leads to downstream signaling events and the migration of activated T cells to sites of inflammation. Herein, we report the third part of our CXCR3 Antagonist program in the field of autoimmunity, culminating in the discovery of the clinical compound ACT-777991 (8a). A previously disclosed advanced molecule was exclusively metabolized by the CYP2D6 Enzyme, and options to address the issue are described. ACT-777991 is a highly potent, insurmountable, and selective CXCR3 Antagonist that showed dose-dependent efficacy and target engagement in a mouse model of acute lung inflammation. The excellent properties and safety profile warranted progress in the clinics.

Figures
Products